rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
|
22536370 |
2012 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
23020132 |
2012 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
22356324 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumours, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.
|
22608338 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF(V600E) mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m(2) intravenously every 3 weeks).
|
22735384 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
23020132 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
22356324 |
2012 |
rs121913377
|
|
TT |
0.800 |
GeneticVariation |
CLINVAR |
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
|
23031422 |
2012 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
|
22048237 |
2012 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
21639808 |
2011 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
21639808 |
2011 |
rs121913377
|
|
AT |
0.800 |
CausalMutation |
CLINVAR |
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
rs121913377
|
|
TT |
0.800 |
GeneticVariation |
CLINVAR |
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
|
21156289 |
2010 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.
|
20818844 |
2010 |
rs113488022
|
|
T |
0.800 |
CausalMutation |
CLINVAR |
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
|
20630094 |
2010 |
rs121913227
|
|
TT |
0.800 |
CausalMutation |
CLINVAR |
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
|
20630094 |
2010 |
rs121913227
|
|
CT |
0.800 |
CausalMutation |
CLINVAR |
Inhibition of mutated, activated BRAF in metastatic melanoma.
|
20818844 |
2010 |